



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts**

**Public declaration of interests**

I, **Jeffrey Yachnin**

**Organisation/Company:** Karolinska University Hospital

**Country:** Sweden

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
02/2018-(current)	Lidds	NZ-DTX-001	F-I-H is being planned for which I have a role as PI and am involved in study design. The therapeutic indication is cutaneous metastases
10/2018-(current)	Oncorena	Orellanine	Renal cancer

2.4 Financial interests

No interest declared

2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
03/2015-04/2019	Novartis	Mekanist, Tafinlar	biliary tract cancer, glioma
02/2016-06/2017	Alligator Bioscience	ADC-1013	solid tumours
04/2016-10/2017	Novartis	INC280	c-Met amplified tumours
01/2017-(current)	Genmab	Tisotumab vedotin	cervix cancer
11/2017-(current)	BMS	BMS-986205	NSCLC, Renal Cancer, Melanom
02/2019-(current)	Alligator Bioscience	ATOR-1017	Solid Tumours
02/2019-(current)	Genentech	R07198457	Solid Tumours
12/2018-(current)	Alligator Bioscience	ATOR-1015	Solid tumours
08/2019-(current)	Cantargia	Can04	Lung and pancreas cancer

## 2.6 Investigator

Period	Company	Products	Therapeutic Indication
05/2015-05/2018	Bayer	Radium-223	prostate cancer
06/2017-(current)	Bayer	Apalutamide	Prostate cancer
07/2016-(current)	Bayer	Apalutamide	Prostate cancer
05/2015-07/2017	Roche	atezoluzimab	urothelial cells cancer
12/2017-(current)	Janssen	Niraparib	prostate cancer
03/2017-(current)	Pfizer	Avelumab	bladder cancer
09/2016-02/2017	MSD	Pembrolizumab	prostate cancer
03/2017-(current)	Astra Zeneca	Lynparza	prostate cancer
01/2019-(current)	Vision	PSMA-Lu177	prostate cancer
03/2019-(current)	Janssen	Niraparib	Prostate cancer
01/2020-(current)	GSK	BCMA conjugate	Myeloma
03/2020-(current)	Novartis	LXH254	melanoma
04/2019-(current)	Academic trial in collaboration with industry: Roche	Atezolizumab	solid tumours
12/2019-(current)	Pfizer	Talazoparib	Prostate Cancer

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

financial support from Sanofi for an academic trial with Jevtana

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

**"EMA Activities"** encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

**"Confidential Information"** means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

**"Confidential Documents"** mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

<b>Full Name:</b>	Jeffrey Yachnin
<b>Date:</b>	2020-03-09

*For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template*